Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

TTI-621 (SIRPαFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Stephen M Ansell, MD PhD, Ian W. Flinn, MD PhD, Michael B. Maris, MD, Owen A. O'Connor, MD, PhD, Alexander Lesokhin, MD, Anjali S. Advani, MD, Mark D. Minden, MD PhD, Mary Beth M. Percival, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Meghan Irwin, BSc, EMBA, Penka S. Petrova, PhD, Robert A. Uger, PhD, Eric L Sievers, MD, Robert W. Chen, MD

Blood (2017) 130 (Supplement 1): 4116.

https://doi.org/10.1182/blood.V130.Suppl_1.4116.4116

Published: 2017

Journal Articles

MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

Neha Korde, MD, Sham Mailankody, MBBS, Eric L Smith, MDPhD, Nikoletta Lendvai, MD PhD, Hani Hassoun, MD, Alexander Lesokhin, MD, Malin Hultcrantz, MD, David J. Chung, MDPhD, Gunjan L. Shah, MD, Guenther Koehne, MDPhD, Heather Landau, MD, Mikhail Roshal, MDPhD, Ahmet Dogan, MD PhD, Sergio A. Giralt, MD, Donna Mastey, RN, Nicole Evancha, Sean M. Devlin, PhD, Ola Landgren, MD PhD

Blood (2017) 130 (Supplement 1): 3133.

https://doi.org/10.1182/blood.V130.Suppl_1.3133.3133

Published: 2017

Journal Articles

Costs and in-Hospital Mortality Rates in Autologous Stem Cell Transplant for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample (NIS) Database

Yuzhou Liu, MD, Hedong Han, MD, Xin Wei, MD, Qian Wang, MD MPH, Jia He, MD PhD, Gunjan L. Shah, MD, Sergio A. Giralt, MD, Ola Landgren, MD PhD, Alexander Lesokhin, MD

Blood (2017) 130 (Supplement 1): 2108.

https://doi.org/10.1182/blood.V130.Suppl_1.2108.2108

Published: 2017

Journal Articles

Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma

Blood (2013) 122 (21): 755.

https://doi.org/10.1182/blood.V122.21.755.755

Published: 2013

Journal Articles

Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma

Nikoletta Lendvai, MD PhD, Heather Landau, MD, Alexander Lesokhin, MD, Ioanna Tsakos, BS, Guenther Koehne, MD, PhD, David Chung, MD PhD, Sean Devlin, PhD, Hani Hassoun, MD, Sergio A Giralt, MD

Blood (2012) 120 (21): 947.

https://doi.org/10.1182/blood.V120.21.947.947

Published: 2012

Journal Articles

Monocytic CCR2+ Myeloid Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T Cell Infiltration Into the Tumor Microenvironment

Alexander Lesokhin, MD, Tobias Hohl, MD, PhD, Taha Merghoub, PhD, Daniel Hirschhorn-cymerman, PhD, Eric G. Pamer, MD, Alan N Houghton, MD, Jedd D Wolchok, MD, PhD

Blood (2011) 118 (21): 2171.

https://doi.org/10.1182/blood.V118.21.2171.2171

Published: 2011

Journal Articles

Adjuvant Bortezomib and Dexamethasone Following Risk-Adapted Melphalan and Stem Cell Transplant in Systemic Light-Chain Amyloidosis (AL): A Phase II Study.

Heather Landau, MD, Hani Hassoun, MD, Adam D Cohen, MD, Alexander Lesokhin, MD, Christina Bello, Elizabeth Hoover, Elyn R Riedel, MD, Jennifer Ciminiello, RN, NP, Emily McCullagh, RN, NP-C, OCN, Stephen D Nimer, MD, Raymond Comenzo, MD

Blood (2009) 114 (22): 533.

https://doi.org/10.1182/blood.V114.22.533.533

Published: 2009

Journal Articles

Outcome of Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation in the Era of Novel Therapies.

Hani Hassoun, MD, Heather Landau, MD, Chirag Surti, Nelly G. Adel, PharmD, Xiaoyu Jia, MS, Elyn R Riedel, MA, Bhutani Manisha, MD, Raymond Comenzo, MD, Alexander Lesokhin, MD, David J. Chung, MD, PhD, Jennifer Ciminiello, NP, Emily McCullagh, RN, NP-C, OCN, Stephen D Nimer, MD

Blood (2009) 114 (22): 1865.

https://doi.org/10.1182/blood.V114.22.1865.1865

Published: 2009

NARROW

TTI-621 (SIRPαFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone

Costs and in-Hospital Mortality Rates in Autologous Stem Cell Transplant for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample (NIS) Database

Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma

Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma

Monocytic CCR2+ Myeloid Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T Cell Infiltration Into the Tumor Microenvironment

Adjuvant Bortezomib and Dexamethasone Following Risk-Adapted Melphalan and Stem Cell Transplant in Systemic Light-Chain Amyloidosis (AL): A Phase II Study.

Outcome of Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation in the Era of Novel Therapies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only